Literature DB >> 10674642

Antimicrobial resistance in Burkholderia pseudomallei.

M Vorachit1, P Chongtrakool, S Arkomsean, S Boonsong.   

Abstract

Four strains of Burkholderia pseudomallei were used to determine the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and time-kill curves with 13 single antimicrobial agents: ceftazidime, piperacillin, imipenem, amoxicillin/clavulanic acid, doxycycline, cotrimoxazole, kanamycin, rifampicin, ciprofloxacin, trovafloxacin, clarithromycin, azithromycin and meropenem. The time-kill studies were also performed with 33 pairs of combinations of the above antimicrobial agents: 15 combinations which would be expected to be used for acute therapy and 18 combinations for maintenance therapy. The results show that the single and combination antimicrobial agents with bactericidal effects against the four strains of B. pseudomallei which should be used for clinical trials in acute melioidosis are: imipenem, meropenem, and imipenem + azithromycin. The combination antimicrobial agents which should be further studied for the ability to eliminate biofilm and intracellular killing effect are ciprofloxacin + clarithromycin, ciprofloxacin + azithromycin, and imipenem + azithromycin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10674642     DOI: 10.1016/s0001-706x(99)00063-7

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  9 in total

1.  In vitro activity of doripenem against Burkholderia pseudomallei.

Authors:  Visanu Thamlikitkul; Suwanna Trakulsomboon
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

Review 2.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

3.  Adaptation and antibiotic tolerance of anaerobic Burkholderia pseudomallei.

Authors:  Mohamad A Hamad; Chad R Austin; Amanda L Stewart; Mike Higgins; Andrés Vázquez-Torres; Martin I Voskuil
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

4.  Temperature-regulated microcolony formation by Burkholderia pseudomallei requires pilA and enhances association with cultured human cells.

Authors:  Justin A Boddey; Cameron P Flegg; Chris J Day; Ifor R Beacham; Ian R Peak
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

5.  Incidence, risk factors and clinical epidemiology of melioidosis: a complex socio-ecological emerging infectious disease in the Alor Setar region of Kedah, Malaysia.

Authors:  Muhammad R A Hassan; Subhada P Pani; Ng P Peng; Kirtanaa Voralu; Natesan Vijayalakshmi; Ranjith Mehanderkar; Norasmidar A Aziz; Edwin Michael
Journal:  BMC Infect Dis       Date:  2010-10-21       Impact factor: 3.090

6.  Cellular reporter screens for inhibitors of Burkholderia pseudomallei targets in Pseudomonas aeruginosa.

Authors:  Donald T Moir; Ming Di; Richard A Moore; Herbert P Schweizer; Donald E Woods
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-12       Impact factor: 2.184

7.  Safer In Vitro Drug Screening Models for Melioidosis Therapy Development.

Authors:  Anna S Amiss; Jessica R Webb; Mark Mayo; Bart J Currie; David J Craik; Sónia Troeira Henriques; Nicole Lawrence
Journal:  Am J Trop Med Hyg       Date:  2020-11       Impact factor: 2.345

8.  BpeAB-OprB, a multidrug efflux pump in Burkholderia pseudomallei.

Authors:  Y Y Chan; T M C Tan; Y M Ong; K L Chua
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

9.  Evaluation of aromatic plants and compounds used to fight multidrug resistant infections.

Authors:  Ramar Perumal Samy; Jayapal Manikandan; Mohammed Al Qahtani
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-08       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.